The Cardiac Amyloidosis Revolution: How ATTR Therapies Are Rewriting Heart Failure Treatment in 2026

For decades, cardiac amyloidosis was a diagnosis cardiologists whispered and patients rarely heard. The disease hides behind the fingerprints of ordinary heart failure. It masquerades as carpal tunnel syndrome. It sits inside aging hearts and waits. By the time doctors identified it, the heart was often too stiff to save. In 2026, that story has changed, and it has changed fast. Four therapies with four completely different mechanisms are now reshaping how cardiologists think about a disease that was considered untreatable less than a decade ago. For anyone interested in how longevity medicine meets real-world cardiology, the transthyretin amyloidosis, or ATTR, story is one of the most important case studies of the current era.

Presented By Our Partners

A Disease Hidden in Plain Sight

ATTR cardiac amyloidosis is caused by misfolded transthyretin protein that slowly infiltrates heart tissue, forming fibrils that stiffen the ventricles. There are two major forms. Wild-type ATTR, sometimes called senile systemic amyloidosis, affects older adults without any inherited mutation. Hereditary ATTR, also called ATTRv or variant ATTR, is driven by genetic changes in the TTR gene, most notably the Val122Ile variant carried by roughly 3 to 4 percent of Black Americans.

The disease has been dramatically underdiagnosed. Studies at major academic medical centers using cardiac bone scintigraphy and genetic testing have repeatedly shown that ATTR accounts for a much larger share of heart failure with preserved ejection fraction, or HFpEF, than anyone suspected. A frequently cited analysis published in the European Heart Journal found that roughly 13 percent of older adults with HFpEF and left ventricular wall thickening had occult wild-type ATTR. Other autopsy series have shown TTR amyloid deposits in as many as a quarter of hearts from people over 80. For most of medical history, these patients were simply labeled as having diastolic heart failure, or hypertensive cardiomyopathy, or, in one of the more telling clinical patterns, bilateral carpal tunnel syndrome followed years later by progressive heart failure.

That carpal tunnel link matters. TTR amyloid preferentially deposits in tendon sheaths and ligaments before it reaches the heart. Patients with wild-type ATTR often undergo carpal tunnel release surgery in their sixties, rotator cuff repair soon after, and develop lumbar spinal stenosis, all while the TTR protein is quietly remodeling their myocardium. Recognizing this prodrome has become one of the most actionable screening strategies in modern cardiology.

The Biology of a Misfolded Protein

Transthyretin is a small protein manufactured in the liver. It circulates as a tetramer, four identical subunits locked together, and its normal job is to transport thyroid hormone and retinol binding protein. In ATTR disease, the tetramer becomes unstable. It dissociates into monomers, which then misfold and aggregate into insoluble amyloid fibrils. Those fibrils infiltrate cardiac tissue, the peripheral nervous system, the autonomic nervous system, and connective tissue throughout the body.

The mutation-driven form can begin in the thirties or forties, depending on the variant. Wild-type disease, in contrast, appears to be a disease of time. The longer a protein circulates, the more opportunity it has to misfold, and the more amyloid accumulates. In that sense, ATTR sits at a philosophical intersection of cardiology and longevity medicine. It is one of the clearest examples of how chronic protein homeostasis failure, the same proteostasis collapse that underlies Alzheimer’s and Parkinson’s disease, also drives age-related cardiac dysfunction.

The Diagnostic Turning Point

The modern era of cardiac amyloidosis began with imaging. In 2016, a landmark multicenter study led by Gillmore and colleagues, published in Circulation, demonstrated that nuclear scintigraphy using technetium pyrophosphate, or Tc-99m PYP, could diagnose ATTR cardiac amyloidosis with extraordinary accuracy. A Perugini grade 2 or 3 cardiac uptake, in the absence of a monoclonal protein, was 100 percent specific for ATTR. For the first time, cardiologists could diagnose the disease without an endomyocardial biopsy. That accessibility alone transformed the field.

Cardiac MRI added texture. Patterns of late gadolinium enhancement, elevated T1 mapping, and increased extracellular volume became hallmarks of amyloid infiltration. Strain echocardiography showed a signature of apical sparing that clinicians learned to spot at the bedside. Combined with gene sequencing, these tools turned a diagnosis that once required invasive biopsy into something that could be made in an afternoon.

The diagnostic infrastructure mattered because it enabled the therapeutic wave that followed. There was no point in treating a disease you could not find. Once cardiologists could find it, the race to treat it accelerated.

Stabilizers: Tafamidis and the ATTR-ACT Legacy

The first approved therapy for ATTR cardiomyopathy was tafamidis, marketed by Pfizer as Vyndaqel and Vyndamax. Tafamidis works by binding the TTR tetramer at the thyroxine binding site, stabilizing it, and preventing the dissociation that triggers amyloid formation.

The pivotal ATTR-ACT trial, published in the New England Journal of Medicine in 2018 by Claudio Rapezzi, Mathew Maurer, and their colleagues, enrolled 441 patients with ATTR cardiomyopathy. After 30 months, tafamidis reduced all-cause mortality by 30 percent and cardiovascular-related hospitalizations by 32 percent compared with placebo. These were historic numbers for a disease that had no disease-modifying therapy. In 2019 the FDA granted approval, and in the years since, tafamidis has become the first-line standard of care for most patients.

Tafamidis is not without limitations. The drug is expensive, its effect takes many months to emerge, and patients with advanced New York Heart Association class III disease still progress on therapy. But it proved a principle. Stabilizing the TTR tetramer could change the natural history of the disease.

Acoramidis: The Second Stabilizer and the Numbers Behind Its Approval

In late 2024, the FDA approved acoramidis, developed by BridgeBio and marketed as Attruby. Acoramidis is a next-generation TTR stabilizer designed to achieve near-complete tetramer stabilization across a wider concentration range than tafamidis.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The ATTRibute-CM trial, published in the New England Journal of Medicine in 2024 with lead author Julian Gillmore, enrolled 632 patients with ATTR cardiomyopathy randomized to acoramidis or placebo on top of background therapy. At 30 months, acoramidis produced a 42 percent reduction in a composite of all-cause mortality and cardiovascular-related hospitalization. It reduced NT-proBNP, a key biomarker of cardiac stress, and preserved six-minute walk distance. Perhaps most notably, the survival and hospitalization curves began separating much earlier than they had in ATTR-ACT, suggesting faster onset of benefit.

Whether acoramidis is superior to tafamidis in head to head terms has not been settled. The two trials used different populations, different endpoints, and different eras of background medical therapy. What matters clinically is that cardiologists now have a choice, and that an entire category of TTR stabilizers has moved from proof of concept to competitive market.

RNA Silencers: Turning Off the Liver’s Amyloid Factory

The most elegant strategy in ATTR medicine is to stop making the bad protein in the first place. Because transthyretin is produced almost exclusively in the liver, it is a near-perfect target for RNA-based therapies delivered to hepatocytes.

Three silencer drugs now dominate this space. Patisiran, marketed by Alnylam as Onpattro, was the first siRNA therapy approved for any disease, and it established RNA interference as a legitimate clinical modality. Vutrisiran, also from Alnylam and marketed as Amvuttra, delivers the same silencing mechanism in a subcutaneous injection given every three months. Eplontersen, developed by Ionis and Akcea and marketed as Wainua, is an antisense oligonucleotide with a similar target profile.

The pivotal HELIOS-B trial, published in the New England Journal of Medicine in 2024 with lead author Marianna Fontana, randomized 655 patients with ATTR cardiomyopathy to vutrisiran or placebo. Over a median follow-up of just over three years, vutrisiran reduced all-cause mortality and recurrent cardiovascular events by 28 percent in the overall population and by 33 percent in the monotherapy group not receiving tafamidis. The trial cemented the idea that silencing TTR production, not merely stabilizing it, produces meaningful clinical benefit in ATTR cardiomyopathy.

Silencers reduce circulating TTR by more than 80 percent. The body, apparently, tolerates this profoundly low TTR concentration without clinically meaningful consequences, a striking biological fact that speaks to the redundancy of thyroid and retinol transport. The clinical question now is whether silencers, stabilizers, or combinations offer the greatest long term benefit. Combination trials are underway.

One and Done? The CRISPR Frontier

The most audacious approach to ATTR is to edit the TTR gene itself. Intellia Therapeutics, in partnership with Regeneron, developed NTLA-2001, an in vivo CRISPR-Cas9 therapy delivered by lipid nanoparticles that travel to the liver and permanently inactivate the TTR gene in hepatocytes.

The first in human data, published in the New England Journal of Medicine in 2021 with lead authors Julian Gillmore and John Maraganore, demonstrated dose-dependent reductions in serum TTR of up to 87 percent after a single intravenous infusion, with no serious adverse events in the initial cohort. Follow up data in 2023 and 2024 extended the evidence base to larger cohorts with sustained knockdown. The ongoing MAGNITUDE trial is testing NTLA-2001, now renamed nexiguran ziclumeran, in patients with ATTR cardiomyopathy, with clinical outcome data expected over the coming years.

If nexiguran ziclumeran ultimately delivers durable safety and clinical benefit, it will represent the first curative approach to a common adult-onset cardiac disease. A single infusion in a single afternoon, with a lifetime of silenced TTR. That is a different kind of medicine than anything cardiology has previously offered.

Why This Story Matters for Longevity

The temptation is to treat ATTR as a niche cardiology topic. That misreads its importance. ATTR is a disease of aging proteostasis, and the therapies now reshaping it are the most advanced human examples of a broader idea that sits at the heart of longevity science. Specifically, that many chronic diseases of aging are driven by protein misfolding and aggregation, and that interrupting that process can meaningfully extend healthspan.

The parallels to Alzheimer’s disease are hard to miss. Both diseases involve misfolded proteins that accumulate over decades. Both involve aging as the dominant risk factor. Both have been transformed, in the past five years, by new imaging biomarkers, new genetic stratification tools, and new therapies that would have been unthinkable a generation ago. ATTR moved faster because the offending protein is made in one organ, travels through blood, and is accessible to liver-targeted therapies. Alzheimer’s amyloid, by contrast, is produced and cleared within the brain, a much harder therapeutic target. But the principle is the same. Target misfolded proteins upstream, not just the downstream tissue damage.

Senescence, another pillar of longevity science, also echoes through ATTR. Senescent cells accumulate misfolded proteins, secrete inflammatory cytokines, and fail to maintain proteostasis. The cellular context of TTR amyloid deposition is an aging environment with declining chaperone activity, declining autophagy, and declining proteasome function. A heart that is already struggling to clear misfolded proteins will accumulate them faster. A body with strong proteostasis defenses, in contrast, may tolerate TTR monomers for decades without harm. That may help explain why wild-type ATTR is a disease of the ninth and tenth decades rather than the sixth, even though TTR instability begins much earlier.

The HFpEF Overlap

Heart failure with preserved ejection fraction is the largest unmet need in modern cardiology. It accounts for half of all heart failure, disproportionately affects older women and Black adults, and has historically been difficult to treat. Two large classes of therapy, SGLT2 inhibitors and mineralocorticoid receptor antagonists, have recently shown meaningful benefit in HFpEF trials. But the realization that a substantial minority of HFpEF patients actually have occult ATTR has added a powerful new dimension to the HFpEF workup.

A practical reframing is now making its way through cardiology practice. In any older adult with left ventricular wall thickness over 12 millimeters, a history of bilateral carpal tunnel syndrome, low voltage on ECG disproportionate to wall thickness, or apical sparing on strain imaging, the next test should include a PYP scan and, if positive, gene sequencing. Making the ATTR diagnosis changes the prognosis, changes the therapy, and, in some patients, changes the family. Hereditary ATTR mutations follow autosomal dominant inheritance, which means confirming the diagnosis in a grandparent often has implications for children and siblings.

Remaining Questions

Even in a year of rapid progress, major uncertainties remain. Head-to-head evidence comparing stabilizers with silencers is still sparse. Combination therapy is plausible but unproven. Cost is a serious issue. Tafamidis alone carries a list price above 200,000 dollars annually in the United States, and silencers and stabilizers together would strain most health systems. Access in lower income countries is essentially absent.

Long-term safety of profound TTR silencing is still being evaluated. Although the short-term data are reassuring, TTR serves as a carrier for thyroid hormone and retinol, and decades of suppressed levels may have subtle consequences that only emerge over time. Vitamin A supplementation is standard for patisiran and silencer recipients, and patients are monitored for ocular effects.

The CRISPR question is existential. If a single infusion can durably silence TTR production with a favorable safety profile, the economics of lifetime stabilizer therapy may unravel. But gene editing introduces its own questions about off-target effects, germline implications of somatic editing, and the practical challenge of rolling out an in vivo CRISPR therapy across large patient populations.

What This Means For You

For most readers, the immediate implication is about awareness, not treatment. If you are over 65 and you or a family member has had bilateral carpal tunnel syndrome, especially followed by rotator cuff problems, lumbar spinal stenosis, or unexplained shortness of breath, ask a cardiologist whether cardiac amyloidosis screening is appropriate. That simple conversation, unheard of a decade ago, may now matter more than any single medication.

If you have African ancestry, ask your primary care doctor about screening for the TTR Val122Ile variant, particularly if there is any family history of heart failure, neuropathy, or early cardiac death. Gene testing is inexpensive and, in the presence of this variant, opens the door to early monitoring and, if necessary, early therapy.

If you have been diagnosed with HFpEF, consider asking whether a PYP scan has been done. Many patients with HFpEF have been managed for years without an amyloidosis workup, and even a single positive scan can change the trajectory of care.

And for the broader question of longevity, the ATTR revolution is worth watching as a template. It shows what becomes possible when diagnosis, genetics, and therapy mature together. Imaging makes the disease visible. Genetics stratifies risk. Stabilizers, silencers, and gene editors each target the problem at different layers. A disease that was invisible and untreatable ten years ago is now diagnosed in minutes and treated with four different mechanisms. That is what maturity looks like in a medical field, and it is the pattern we should expect to see applied to Alzheimer’s disease, Parkinson’s disease, and other chronic diseases of aging over the coming decade.

The quiet victory of cardiac amyloidosis medicine is not just that it saved a neglected group of patients. It is that it validated a broader vision of longevity medicine, one in which aging is not a single process but a collection of targetable molecular failures, each of which yields to the right tool at the right time.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.